Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

@article{Weber2015NivolumabVC,
  title={Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.},
  author={Jeffrey S. Weber and Sandra P. D'Angelo and David R. Minor and Frank Stephen Hodi and Michael R. Migden and Bart Neyns and Christoph Hoeller and Nikhil I. Khushalani and Wilson H Jr Miller and Christopher D. Lao and Gerald P. Linette and L Thompson Thomas and Paul C. Lorigan and Kenneth F. Grossmann and Jessica C Hassel and Michele Maio and Mario Sznol and Paolo Antonio Ascierto and Peter Dipl.-Ing. Mohr and Bartosz Chmielowski and Alan H Bryce and Inge Marie Svane and Jean-Jacques Grob and Angela M. Krackhardt and Christine E. Horak and Alexandre M Lambert and Arvin S. Yang and James Michael Larkin},
  journal={The Lancet. Oncology},
  year={2015},
  volume={16 4},
  pages={
          375-84
        }
}
BACKGROUND Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses in patients with melanoma who have progressed after ipilimumab and BRAF inhibitors. We assessed the efficacy and safety of nivolumab compared with investigator's choice of chemotherapy (ICC) as a second-line or later-line treatment in patients with advanced melanoma. METHODS In this randomised, controlled, open-label, phase 3 trial, we recruited patients at 90 sites in 14… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 730 CITATIONS, ESTIMATED 50% COVERAGE

First-line treatment of metastatic melanoma: role of nivolumab

  • ImmunoTargets and therapy
  • 2017
VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2017
VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma: A nursing perspective.

  • Journal of the American Association of Nurse Practitioners
  • 2017
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

CTLA-4 and PD-1 Pathways

  • American journal of clinical oncology
  • 2016
VIEW 4 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

Immune checkpoint inhibitors: therapeutic advances in melanoma.

  • Annals of translational medicine
  • 2015
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2013
2019

CITATION STATISTICS

  • 40 Highly Influenced Citations

  • Averaged 159 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

A Ribas, I Puzanov, R Dummer
  • 2014

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014